Obstet Gynecol Sci.  2016 Mar;59(2):116-122. 10.5468/ogs.2016.59.2.116.

Prognostic factors in neuroendocrine cervical carcinoma

Affiliations
  • 1Department of Obstetrics and Gynecology, Seoul National University Hospital, Seoul, Korea. marialeemd@gmail.com
  • 2Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul, Korea.
  • 3Center for Uterine Cancer, Research Institute and Hospital, National Cancer Center, Goyang, Korea.

Abstract


OBJECTIVE
To evaluate the clinical and pathologic factors associated with survival in patients with neuroendocrine cervical carcinoma (NECC).
METHODS
The records of 61 patients with NECC diagnosed between 2000 and 2014 at Seoul National University Hospital and the National Cancer Center were retrospectively reviewed. Kaplan-Meier and Cox regression methods were used for analyses.
RESULTS
Of the 61 patients, 67.2% were diagnosed at early stage (I to IIA) with a median age of 49 years. Of those, 78% underwent surgery and 75.6% received postoperative adjuvant treatment. For patients diagnosed at advanced stage, 60.0% received chemotherapy only and 25.0% received concurrent chemoradiation therapy. In the univariate analysis, advanced stage (77 vs. 40 months, P=0.013), tumor size ≥2 cm (133 vs. 47 months, P=0.002) and mixed tumor (101 vs. 34 months, P=0.004) were shown to be poor prognostic factors. In the multivariate analysis, tumor stage, tumor size and tumor homology were shown to be independent prognostic factors for overall survival. Of the total, 39.3% of the patients experienced recurrence, and 54.1% of the patients had metastasis. Of the patients diagnosed at early stage, 51.2% experienced recurrence.
CONCLUSION
Tumor stage, tumor size and tumor homology were found to be independent prognostic factors in patients with NECC. Even in patients diagnosed at early stage, recurrence and distant metastasis were frequently observed.

Keyword

Cervical carcinoma; Neoplasm recurrence; Neuroendocrine carcinoma; Retrospective studies; Small cell carcinoma

MeSH Terms

Carcinoma, Neuroendocrine
Carcinoma, Small Cell
Drug Therapy
Humans
Multivariate Analysis
Neoplasm Metastasis
Recurrence
Retrospective Studies
Seoul

Figure

  • Fig. 1 Overall survival estimates stratified by (A) tumor stage, (B) tumor size in all stage, (C) tumor size in early stage, and (D) tumor homology.


Reference

1. Albores-Saavedra J, Gersell D, Gilks CB, Henson DE, Lindberg G, Santiago H, et al. Terminology of endocrine tumors of the uterine cervix: results of a workshop sponsored by the College of American Pathologists and the National Cancer Institute. Arch Pathol Lab Med. 1997; 121:34–39.
2. Gardner GJ, Reidy-Lagunes D, Gehrig PA. Neuroendocrine tumors of the gynecologic tract: a Society of Gynecologic Oncology (SGO) clinical document. Gynecol Oncol. 2011; 122:190–198.
3. Delaloge S, Pautier P, Kerbrat P, Castaigne D, Haie-Meder C, Duvillard P, et al. Neuroendocrine small cell carcinoma of the uterine cervix: what disease? What treatment? Report of ten cases and a review of the literature. Clin Oncol (R Coll Radiol). 2000; 12:357–362.
4. Viswanathan AN, Deavers MT, Jhingran A, Ramirez PT, Levenback C, Eifel PJ. Small cell neuroendocrine carcinoma of the cervix: outcome and patterns of recurrence. Gynecol Oncol. 2004; 93:27–33.
5. Hoskins PJ, Swenerton KD, Pike JA, Lim P, Aquino-Parsons C, Wong F, et al. Small-cell carcinoma of the cervix: fourteen years of experience at a single institution using a combined-modality regimen of involved-field irradiation and platinum-based combination chemotherapy. J Clin Oncol. 2003; 21:3495–3501.
6. Chen TC, Huang HJ, Wang TY, Yang LY, Chen CH, Cheng YM, et al. Primary surgery versus primary radiation therapy for FIGO stages I-II small cell carcinoma of the uterine cervix: a retrospective Taiwanese Gynecologic Oncology Group study. Gynecol Oncol. 2015; 137:468–473.
7. Lee JM, Lee KB, Nam JH, Ryu SY, Bae DS, Park JT, et al. Prognostic factors in FIGO stage IB-IIA small cell neuroendocrine carcinoma of the uterine cervix treated surgically: results of a multi-center retrospective Korean study. Ann Oncol. 2008; 19:321–326.
8. Tsuchiya R, Suzuki K, Ichinose Y, Watanabe Y, Yasumitsu T, Ishizuka N, et al. Phase II trial of postoperative adjuvant cisplatin and etoposide in patients with completely resected stage I-IIIa small cell lung cancer: the Japan Clinical Oncology Lung Cancer Study Group Trial (JCOG9101). J Thorac Cardiovasc Surg. 2005; 129:977–983.
9. Cohen JG, Kapp DS, Shin JY, Urban R, Sherman AE, Chen LM, et al. Small cell carcinoma of the cervix: treatment and survival outcomes of 188 patients. Am J Obstet Gynecol. 2010; 203:347.e1–347.e6.
10. Deacon JM, Evans CD, Yule R, Desai M, Binns W, Taylor C, et al. Sexual behaviour and smoking as determinants of cervical HPV infection and of CIN3 among those infected: a case-control study nested within the Manchester cohort. Br J Cancer. 2000; 83:1565–1572.
11. Chan JK, Loizzi V, Burger RA, Rutgers J, Monk BJ. Prognostic factors in neuroendocrine small cell cervical carcinoma: a multivariate analysis. Cancer. 2003; 97:568–574.
12. Chang TC, Lai CH, Tseng CJ, Hsueh S, Huang KG, Chou HH. Prognostic factors in surgically treated small cell cervical carcinoma followed by adjuvant chemotherapy. Cancer. 1998; 83:712–718.
13. Bermudez A, Vighi S, Garcia A, Sardi J. Neuroendocrine cervical carcinoma: a diagnostic and therapeutic challenge. Gynecol Oncol. 2001; 82:32–39.
14. Huang L, Liao LM, Liu AW, Wu JB, Cheng XL, Lin JX, et al. Analysis of the impact of platinum-based combination chemotherapy in small cell cervical carcinoma: a multicenter retrospective study in Chinese patients. BMC Cancer. 2014; 14:140.
Full Text Links
  • OGS
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr